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Abstract
Objective: Effects of aprotinin in off-pump coronary artery bypass (OPCAB) surgery have not yet been described. This study analyses
hemostasiologic changes and potential benefit in OPCAB patients treated with aprotinin. Methods: In a prospective, double-blind, rando-
mized study 47 patients undergoing OPCAB surgery were investigated. Patients received either aprotinin (2 £ 106 KIU loading dose and
0.5 £ 106 KIU/h during surgery, n ¼ 22) or saline solution (control, n ¼ 25). Activated clotting time was adjusted to a target of 250 s
intraoperatively. Blood samples were taken up to 18 h postoperatively: complete hematologic and hemostasiologic parameters including
fibrinopeptide A (FPA) and D-dimer in a subgroup of 31 patients were analyzed. Blood loss, blood transfusion and other clinical data were
collected. Results: Both groups showed comparable demographic and intraoperative variables. Forty-one (87%) patients of the whole study
group received aspirin within 7 days prior to surgery. Number of grafts per patient were comparable (2.9 ^ 1.0 [mean ^ SD] in the aprotinin
group and 2.8 ^ 1.2 in control, P ¼ 0:83). Blood loss during the first 18 h in intensive care unit was significantly reduced in patients treated
with aprotinin (median [25th–75th percentiles]: 500 [395–755] ml vs. 930 [800–1170] ml, P , 0:001). Postoperatively only two patients
(10%) in the aprotinin group received packed red blood cells, whereas eight (35%) in the control group ðP ¼ 0:07Þ. Perioperatively FPA
levels reflecting thrombin generation were elevated in both groups. The increase in D-dimer levels after surgery was significantly inhibited in
the aprotinin group ðP , 0:001Þ. Early clinical outcome was similar in both groups. Conclusions: Aprotinin significantly reduces blood loss
in patients undergoing OPCAB surgery. Inhibition of enhanced fibrinolysis can be observed. FPA generation during and after OPCAB
surgery seems not to be influenced by aprotinin. q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Coronary artery bypass grafting (CABG) with cardiopul-
monary bypass (CPB) has evolved a safe procedure with
low mortality rates in the last decades. However, extracor-
poreal circulation and its influence on hemostasis, platelet
count and function may lead to increased postoperative
bleeding, substantial need for foreign blood transfusion
and morbidity [1]. In order to reduce CPB associated
morbidity, off-pump coronary artery bypass (OPCAB)
procedures have gained popularity. Although postoperative
bleeding seems to be attenuated by the avoidance of CPB,
hemorrhagic complications are not completely eliminated
and there is still a need for blood transfusion after
OPCAB surgery [2–4].
Aprotinin, a non-specific protease inhibitor, is proven to
reduce blood loss and transfusion requirements in on-pump
cardiac surgery. In many centers aprotinin is now used on a
routine basis for on-pump CABG cases. The aim of this
study was to evaluate the hemostatic effects of aprotinin
in OPCAB surgery.
2. Material and methods
Forty-nine patients scheduled for elective CABG and
supposed to be operated with off-pump techniques were
enrolled in this prospective, double-blind, randomized
study. Exclusion criteria were the following: previous
cardiac surgery, left ventricular ejection fraction ,0.35,
myocardial infarction ,7 days before surgery, neurologic
disorders (e.g. cerebrovascular accident), severe pulmonary
disorders, renal failure (elevation of creatinine and urea),
liver diseases, active inflammatory disease, preoperative
coagulopathies, and previous aprotinin therapy. Patients
receiving aspirin, other antiplatelet drug or heparin were
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included in the study. Study protocol was approved by the
ethical committee on human research of Berne (6/2000, April
12, 2000). Written informed consent was obtained from all
patients. Two patients (4%) were converted to on-pump
CABG and were excluded from the study. Patients were
randomly allocated to either the aprotinin group (A,
n ¼ 22) or the control group (C, n ¼ 25). In the aprotinin
group a loading dose at the beginning of surgery (2 £ 106
KIU ¼ 280 mg) was administered followed by continuous
infusion of 0.5 £ 106 KIU throughout surgery. In group C
the same volume of saline solution was infused. Fifty milli-
liter bottles with the study drug (0.5 £ 106 KIU ¼ 70 mg
aprotinin) or with saline solution were numbered continu-
ously. For each number eight bottles with the same content
were available. Blinding of the bottles was performed by
personal of the hospital pharmacy, not involved otherwise
in the study.
2.1. Anesthesia, operation and postoperative care
All patients had premedication with benzodiazepines.
General anesthesia was induced and maintained with mida-
zolam, fentanyl and inhalatives (isoflurane or enflurane).
Muscle relaxation was achieved with pancuronium
bromide. Standard monitoring methods including electro-
cardiography, radial artery line, central venous catheter,
two peripheral venous catheters, urinary catheter and rectal
temperature measurement were used in all patients.
All patients were operated on according to a standardized
surgical protocol. After full midline sternotomy the left
internal mammary artery was harvested in all patients,
together with additional graft material (saphenous vein
and/or radial artery). Stabilization of the beating heart was
established with the Octopusw tissue stabilizer (Medtronic
Inc., Minneapolis, MN, USA).
Heparin IV was administered after harvesting the internal
mammary artery to achieve systemic anticoagulation during
surgery by an initial dose between 70 and 100 units/kg
bodyweight. Activated clotting time (ACT) was adjusted
to a target of 250 s intraoperatively. ACT was measured
using a kaolin-activated system (Automated coagulation
timer ACT II, Medtronic HemoTec Inc., Englewood, FL,
USA). Standard use of protamine after the procedure was
not intended. It was only given if clinically increased bleed-
ing in the operating field was observed and/or if the ACT
value was still over 200 s at the end of surgery. A cell-
saving device was not used. Intraoperatively no blood was
retransfused. Transfusion of packed red blood cells was
performed if the hematocrit was less than 23%. Before
chest closure, mediastinal and pleural drains were inserted
and low-grade suction (20 cm H2O) was performed. Blood
loss was recorded at arrival in the intensive care unit (ICU),
2, 6, 12 and 18 h after surgery.
In ICU the patients were treated according to routine
protocol. Up to 12 h after surgery shed mediastinal blood
was retransfused (Autotransfusion Reservoir, Jostra Medi-
zintechnik, Hirrlingen, Germany) if necessary (hemoglobin
,90 g/l and total drainage volume exceeded 250 ml). A red
blood cell transfusion was administered when hemoglobin
decreased to less than 85 g/l. Transfusion of fresh frozen
plasma was indicated to correct suspected deficiency of
coagulation factors when drain production was increased
(.200 ml/h). Prophylactic measures were started at the
first postoperative day with orally given aspirin (100 mg
once per day) and subcutaneous injection of low-molecu-
lar-weight heparin (weight-adapted dosage once per day).
2.2. Laboratory analyses
Perioperatively, routine hematologic (hemoglobin, hema-
tocrit, platelet count) and hematochemical parameters such
as creatinine, creatine phosphokinase (CK) including its iso-
enzyme MB and Troponin I were collected in all patients
and the samples were analyzed by the central laboratory of
the hospital for routine analysis.
In a subgroup of patients (n ¼ 16 in group A, n ¼ 15 in the
control group) arterial blood samples were collected at six
different time points to determine fibrinopeptide A (FPA) and
D-dimer: preoperatively, after induction of anesthesia (base-
line); during distal anastomoses; at the end of surgery; 2, 6
and 18 h postoperatively. To determine parameters of coagu-
lation and fibrinolysis blood was used treated with CTADP-
PACK anticoagulant. Immediately the corpuscular content
was separated from the fluid phase by centrifugation at 2000g
for 15 min at 68C. Plasma was aliquoted and stored at2708C
before being assayed. FPA was measured using a radioim-
munoassay (RIA), (IMCO Corporation Ltd AB, Stockholm,
Sweden). D-dimer (Dimertestw, Agen Biomedical, Acacia
Ridge, Australia) which reflects the fibrinolytic status was
measured using enzyme-linked immunosorbent assay
(ELISA) techniques. All samples were assayed in duplicate
and the mean value was retained.
2.3. Statistical analysis
Statistical analysis was carried out using standard soft-
ware (StatView 5.0.1, SAS Institute Inc., Cary, NC, USA).
Data are presented as median [25th percentile; 75th percen-
tile] or as mean ^ SD if appropriate. Normally distributed
data were analyzed with two-tailed unpaired t-test. A chi-
square analysis or Fisher’s exact test was used for categorial
data. Non-parametric evaluation was performed for vari-
ables not normally distributed (Mann–Whitney U test).
Laboratory results were tested within the groups to detect
time interactions (Friedman test). If statistically significant
changes were seen, signed-rank testing was post hoc used to
locate the differences. Differences between the groups were
analyzed using two-group non-parametrical testing (Mann–
Whitney U). For repeatedly measured variables additional
global testing (analysis of variance (ANOVA)) for both
groups was performed. For multiple testing Bonferroni
correction was performed. A P value less then 0.05 was
considered statistically significant.
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3. Results
Both groups showed comparable demographic and intrao-
perative variables (Table 1). No statistically significant
differences were noted between the groups with respect to
mean age, gender, body mass index, left ventricular function,
mean duration of the operation and number of grafts per
patient. Forty-one (87%) patients of the whole study group
received aspirin within 7 days prior to surgery (Table 1).
Two patients (one in each group) required reexploration
because of bleeding. In both patients a surgical cause of
bleeding was detected. One patient of the control group
had signs of myocardial ischemia with hemodynamic
instability after surgery and was transferred back to the oper-
ating room. Spasm of the radial graft to the obtuse marginal
was detected and a venous graft to the marginal branch was
performed with CPB. The postoperative variables of these
three patients (laboratory results, blood loss and transfusion-
requirements) were not included in the analysis.
Heparin dose did not differ between the groups (Table 1).
In both groups ACT levels were measured in the adjusted
range after heparin (230 [210–295] s in the aprotinin group
vs. 243 [203–284] s in control, P ¼ 0:98) and returned to
baseline values 2 h postoperatively (110 [98–131] s vs. 103
[86–115] s, P ¼ 0:16). At the end of surgery ACT values
were 197 [168–243] s and 191 [154–218] s, respectively
ðP ¼ 0:30Þ. Protamine was administrated only in a minority
of patients (Table 1).
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Table 1
Demographics and intraoperative characteristicsa
Control group (n ¼ 25) Aprotinin group (n ¼ 22) P value
Age (years) 66.4 ^ 9.0 63.9 ^ 10.8 0.40
Gender (male/female) 19/6 16/6 0.63
Weight (kg) 77.1 ^ 8.6 74.6 ^ 14.1 0.46
Body mass index (kg/m2) 27.8 ^ 3.6 27.1 ^ 4.4 0.51
Diseased vessels (no.) 2.4 ^ 0.9 2.3 ^ 0.7 0.54
Previous MI (no. of pts) 10 (40%) 13 (59%) 0.19
LV ejection fraction (%) 60 ^ 13 65 ^ 13 0.14
Unstable angina (no. of pts) 8 (32%) 6 (27%) 0.72
Preoperative aspirin (no.of pts) 23 (92%) 18 (82%) 0.40
Preoperative heparin (no. of pts) 4 (16%) 2 (9%) 0.67
Operating time (min) 177 ^ 56 176 ^ 40 0.98
No. of grafts 2.8 ^ 1.2 2.9 ^ 1.0 0.83
Pts. with IMA grafts (no.) 25 (100%) 22 (100%) –
Pts. with radial grafts (no.) 10 (40%) 11 (50%) 0.49
PAR (no. of pts) 11 (44%) 9 (41%) 0.83
Heparin (U/kg) 80 ^ 14 85 ^ 17 0.35
Protamine given (no. of pts)
At the end of surgery 3 2 –
During ICU stay 2 1 –
a Data are mean ^ standard deviation unless otherwise specified (MI ¼ myocardial infarction; LV ¼ left ventricular; IMA ¼ internal mammary artery;
PAR ¼ pure arterial revascularization; ICU ¼ intensive care unit).
Table 2
Postoperative blood loss and transfusionsa
Control group (n ¼ 23) Aprotinin group (n ¼ 21) P value
Postoperative blood loss (ml)
At 2 h 150 [118–394] 100 [50–200] 0.23*
At 6 h 450 [300–675] 230 [158–413] , 0.05*
At 12 h 725 [445–1008] 400 [258–520] , 0.01*
At 18 h 930 [800–1170] 500 [395–755] , 0.001*
Retransfusion (no. of pts) 9 (39%) 7 (33%) 0.69
Median volume (ml) 800 [480–875] 500 [300–700] 0.09
PRBC received (no. of pts)
Intraoperatively 1 1 –
Postoperatively 8 (35%) 2 (10%) 0.07
FFP received (no. of pts) 4 (17%) 0 (0%) 0.11
Platelet concentrates (no.) 0 0 –
a Data are median [25th–75th percentiles] unless otherwise indicated.
* Corrected values for multiple testing (PRBC ¼ packed red blood cells; FFP ¼ fresh-frozen plasma).
Blood loss during the first 2 h in ICU did not differ signif-
icantly between the groups whereas at the following time
points patients treated with aprotinin had highly significant
less blood loss than the control group (500 [395–755] ml vs.
930 [800–1170] ml, P , 0:001). Postoperatively only two
patients (10%) in the aprotinin group received packed red
blood cells, whereas eight (35%) received in the control
group ðP ¼ 0:07Þ. Only four patients received fresh-frozen
plasma, all in the control group ðP ¼ 0:11Þ. No patient of
either group had transfusion of platelet concentrates (Table
2).
Routine hematological and hematochemical data
compared preoperatively and at the first postoperative day
showed no significant differences between the groups (Table
3).
Early clinical outcome was similar in both groups. The
incidence of adverse events during hospitalization was
comparable in both groups (Table 4). The patient who
required reoperation because of a radial artery spasm
suffered from perioperative myocardial infarction, a neuro-
logical impairment, a prolonged ventilation time and a tran-
sient renal failure with the need for dialysis.
3.1. Fibrinopeptide A and D-dimer
As indicator of thrombin formation, the plasma concen-
tration of FPA was elevated perioperatively with peak
values at the end of surgery (21.2 [16.9–28.6] ng/ml in the
aprotinin group and 25.6 [21.2–28.8] ng/ml in control). Six
hours postoperatively median values were higher in the
control group (7.4 [5.2–10.6] ng/ml vs. 18.8 [10.6–25.3]
ng/ml, P , 0:01). Nevertheless, global testing showed no
significant treatment interaction between the groups
ðP ¼ 0:61Þ. Furthermore, eliminating values of patients
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Table 3
Perioperative hematochemical dataa
Control group (n ¼ 25) Aprotinin group (n ¼ 22) P value
Hemoglobin (g/l)
Preoperative 143 [128–150] 136 [126–143] 0.15
First POD 100 [94–111] 106 [93–120] 0.32
Hematocrit
Preoperative 0.43 [0.38–0.45] 0.40 [0.38–0.43] 0.14
First POD 0.29 [0.28–0.32] 0.31 [0.28–0.35] 0.24
Platelet count (109/l)
Preoperative 254 [183–322] 262 [202–310] 0.61
First POD 199 [142–236] 176 [156–212] 0.79
Creatinine (mmol/l)
Preoperative 94 [84–102] 92 [83–110] 0.99
First POD 84 [76–93] 85 [76–96] 0.96
CK total (U/l)
Preoperative 67 [53–94] 82 [54–131] 0.50
First POD 423 [299–690] 544 [388–658] 0.62
CK-MB (U/l) 10.2 [5.3–19.2] 10.4 [6.7-22.8] 0.66
Troponin I (mg/l) 3.5 [1.6–14.1] 3.7 [2.9–10.9] 0.91
a Data are median [25th–75th percentiles] (POD ¼ postoperative day; CK ¼ creatine phosphokinase).
Table 4
Outcome variablesa
Control group (n ¼ 25) Aprotinin group (n ¼ 22)
Re-exploration (bleeding) 1 1
Re-operation 1* 0
Perioperative MI 1 1
Neurological deficit 1 0
Respiratory dysfunction (ventilation. 24 h) 1 1
Renal dysfunction (creatinine. 200 mg/l) 1** 1
Ventilation time (h) 11.6 ^ 18.9 (7.5) 9.8 ^ 6.8 (7.3)
Hospitalization (days) 9.1 ^ 8.0 (8.0) 8.0 ^ 2.2 (8.0)
Mortality 0 0
a Data are mean ^ standard deviation (median) unless otherwise indicated. No significant intergroup differences were found (ICU ¼ intensive care unit;
MI ¼ myocardial infarction.
* due to spasm of a radial graft.
** with passager dialysis).
who had postoperative retransfusion of mediastinal shed
blood (7/16 in the aprotinin subgroup and 7/15 in control),
the difference was minimized (9.0 [7.6–13.2] ng/ml vs. 11.1
[9.8–18.0] ng/ml, P ¼ 0:30). Overall, elevated median
values of FPA at the end of surgery compared to baseline
in both groups demonstrate reasonable generation of throm-
bin. Significant influence of aprotinin was not detected
(Fig. 1).
Preoperative median levels of D-dimer were comparable
in both groups. Postoperatively, both groups showed signif-
icantly elevated levels of D-dimer compared to baseline. At
the end of surgery and at the following sampling points up to
18 h postoperatively a highly significant difference between
the groups was detected. The increase in D-dimer levels
after surgery was significantly inhibited in the aprotinin
group ðP , 0:001Þ, (Fig. 2). Significant intergroup differ-
ences persisted, if the patients with postoperative retransfu-
sion of mediastinal shed blood were excluded from analysis.
4. Discussion
It is well recognized that aprotinin reduces both, blood loss
and the need for foreign blood-product transfusion following
CABG with CPB [5,6]. During the recent years an increasing
number of OPCAB procedures have been performed.
However, beneficial effects of aprotinin have not yet been
tested in this setting. Besides, its hemostatic effects in cardiac
surgery the efficacy of aprotinin has been demonstrated in
other surgical disciplines (e.g. liver, thoracic and major
orthopedic surgery) [7–9] but not in open abdominal aneur-
ysm repair [10]. Some previous reports have demonstrated
decreased perioperative bleeding and reduced use of foreign
blood products in OPCAB surgery compared to CABG with
extracorporeal circulation; nevertheless, postoperative blood
loss following OPCAB surgery cannot be neglected [2–4].
Our own experience demonstrates an increasing proportion
of patients operated without cessation of antiplatelet therapy.
Additionally it has been described, that bleeding complica-
tions occurring may be controlled and/or compensated by the
routine use of aprotinin [11,12]. In this prospective, double-
blind, randomized study we evaluated the effectiveness of
aprotinin in OPCAB surgery.
The main end-point ‘postoperative blood loss’ showed a
highly significant effect of aprotinin with reduced blood loss
in the treatment group. Consecutively, less patients in the
aprotinin group received foreign blood products (35% vs.
10%) in the postoperative course. However, the difference
between the two groups did not reach statistical significance
ðP ¼ 0:07Þ in our limited number of study patients, even
though it seems to be clinically relevant. The proportion
of patients who received postoperative retransfusion were
comparable, but not the retransfused volume, which tends to
be lower in patients treated with aprotinin (Table 2). Over-
all, our data demonstrate relevant clinical efficacy of apro-
tinin in OPCAB patients.
In order to investigate the effects of aprotinin on coagula-
tion and the fibrinolytic system in OPCAB patients, two
important plasmatic markers (FPA and D-dimer, respec-
tively) were determined in a subgroup of 31 patients. The
coagulation product FPA was elevated perioperatively in
both groups; this reflects activation of thrombin which has
been described also otherwise in major surgery [13] and in
OPCAB procedures [14]. Intraoperative anticoagulation
was performed with weight-adjusted heparin (70–100 U/
kg bodyweight in all patients) and ACT value of 250 s
was targeted. Reversal with protamine was performed
only in a minority of patients. No thrombembolic complica-
tion occurred in our study population. So far concerns raised
about procoagulant activity after OPCAB surgery [14] can
be supported only in biochemical terms. In addition, 100 U/
kg heparin seems to become the standard in OPCAB proce-
dures, and recent investigations did not show a higher inci-
dence of thrombotic complications in OPCAB surgery [15].
Nevertheless, aprotinin had no significant impact on the
median levels of FPA in our study cohort, despite others
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Fig. 1. Fibrinopeptide A (FPA). Data are presented as median. Error bars
indicate 25th and 75th percentiles.1, significant higher values compared to
baseline ðP , 0:05Þ. *, significant intergroup difference ðP , 0:01Þ (H ¼
hours postoperatively).
Fig. 2. Levels of D-dimer. Data are presented as median. Error bars indicate
25th and 75th percentiles. Higher values compared to baseline in both
groups (1P , 0:05; 11 P , 0:01). Significant intergroup differences
(*P , 0:05; **P , 0:01; ***P , 0:001) (H ¼ hours postoperatively).
having hypothesized anticoagulative/antithrombotic effects
of this drug [16–18]. Detected higher values of FPA in the
control group 6 h postoperatively seem to be confounded by
retransfused mediastinal shed blood in some patients during
the first postoperative hours. Retransfused mediastinal shed
blood may be strongly activated and contains some coagu-
lation products in a high concentration [19]. On the other
hand, concerns regarding thrombotic complications with the
use of aprotinin have been raised. This has led to the recom-
mendation of higher ACT levels during surgery if aprotinin
is used [20]. However, this cannot be disproved by studies
with small sample sizes, although these concerns may be
partially explained by the use of different types of activators
for ACT measurement [20]. In our study ACT levels were
determined using a kaolin-activated system that in contrast
to celite-activation does not produce prolonged ACT values
in the presence of aprotinin [16,21].
Looking at the fibrinolytic system we found significantly
higher values of D-dimer in the control group. Intergroup
difference was already seen at the end of surgery and
marked in the postoperative hours. This underlines that
improved hemostasis is achieved at least partly by the anti-
fibrinolytic action of aprotinin.
Although antifibrinolytics have been used routinely in
cardiac surgery with extracorporeal circulation this measure
is not yet established in OPCAB surgery. Recently, Casati et
al. [22] demonstrated the effectiveness of the synthetic anti-
fibrinolytic drug tranexamic acid in OPCAB patients.
Compared to synthetic substances, the non-specific protease
inhibitor aprotinin, isolated from bovine lung tissue, seems
to be important not only as an antifibrinolytic agent but also
as a modulator of the endothelial function [23] and the
inflammatory process [24] and may have superior effects
than other drugs [25].
More than 80% of the patients in our study received
aspirin within 7 days prior to surgery. We conclude that
aprotinin should be considered as adjunct in OPCAB
surgery especially in these patients with an increased risk
of perioperative bleeding.
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